Sanofi SA
SNYNF
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
74,846
Sanofi SA News & Analysis
markets
Globalisation declining? Not in investor portfolios
Morningstar Indexes through a geographic revenue lens.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,424.10 | 13.30 | -0.14% |
| CAC 40 | 8,726.03 | 11.10 | 0.13% |
| DAX 40 | 26,355.07 | 35.62 | 0.14% |
| Dow JONES (US) | 53,968.26 | 68.67 | -0.13% |
| FTSE 100 | 10,862.50 | 38.59 | -0.35% |
| HKSE | 25,937.49 | 269.46 | 1.05% |
| NASDAQ | 26,640.68 | 49.94 | -0.19% |
| Nikkei 225 | 66,970.22 | 1,363.51 | 2.08% |
| NZX 50 Index | 13,888.24 | 64.11 | 0.46% |
| S&P 500 | 7,761.65 | 4.01 | 0.05% |
| S&P/ASX 200 | 9,232.60 | 17.00 | -0.18% |
| SSE Composite Index | 3,966.59 | 26.56 | 0.67% |